AbbVie Inc ABBV announced topline results from the single-arm Phase 2 LUMINOSITY trial evaluating telisotuzumab-vedotin (Teliso-V) in patients with c-Met protein overexpression, epidermal growth factor receptor (EGFR) wild type, advanced/metastatic nonsquamous non-small cell lung cancer (NSCLC).
The results demonstrated a compelling overall response rate per independent central review (ICR) of 35% and 23% across c-Met High and c-Met Intermediate patients, respectively.
In addition, other endpoints demonstrated meaningful clinical outcomes, including a median duration of response per ICR of 9 months and 7.2 months and a median overall survival of 14.6 months and 14.2 months across c-Met High and c-Met Intermediate patients, respectively.
The safety profile of Teliso-V was consistent with previous findings, and no new safety concerns were identified. Adverse events with Teliso-V monotherapy were generally well managed and tolerated.
Approximately 85% of lung cancers are classified as NSCLC. C-Met protein overexpression is found in approximately 25% of advanced EGFR wild-type NSCLC patients.
Teliso-V is being evaluated as a monotherapy in patients with previously treated c-Met overexpressing EGFR wild-type nonsquamous NSCLC in the randomized Phase 3 study TeliMET NSCLC-01, which is currently enrolling.
Price Action: ABBV shares are up 0.60% at $138.91 on the last check Wednesday.
Photo Via Company
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
